Literature DB >> 10423148

Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1.

A Grabowska, C Jameson, P Laing, S Jeansson, E Sj Gren-Jansson, J Taylor, A Cunningham, W L Irving.   

Abstract

A combination of phage peptide display library mapping and pepscanning, with both murine monoclonal antibodies and a panel of well-characterized human sera, have been used in order to define type-specific epitopes of glycoprotein G of herpes simplex virus type 2 (HSV-2) (gG2). Both techniques revealed an immunodominant region of gG2, centred around amino acids 525-587 of the uncleaved gG2 molecule. A soluble peptide, equivalent to amino acids 551-570, when used as antigen in an ELISA format was recognized by three out of five murine MAbs and by 20/26 (77%) Western blot anti-HSV-2-positive human sera, but by only 1/63 Western blot anti-HSV-2-negative sera (specificity, 98%). The sensitivity of detection of human anti-HSV-2 antibodies was increased to 90% using a peptide derived from this region, presented on a nitrocellulose membrane. This highly antigenic and type-specific domain of gG2 is located at the junction between the 'unique' region of gG2 and its C-terminal end, which has approximately 50% identity with gG1. A second antigenic region of gG2, amino acids 351-427, which lies within the 'unique' part of gG2, was also identified by both techniques employed in this study and is recognized by a proportion of anti-HSV-2-positive sera. These findings demonstrate the feasibility of developing a peptide-based type-specific assay for the detection of anti-HSV-2 antibody in human sera based on type-specific epitopes of gG2 and have implications for the understanding of the three-dimensional topography of gG2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423148     DOI: 10.1099/0022-1317-80-7-1789

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates.

Authors:  J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential.

Authors:  Tao Liu; Ji Feng Liu; Hua Yu; Guo Jing Si; Jun Hu; Jun Li
Journal:  Singapore Med J       Date:  2015-06       Impact factor: 1.858

5.  Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins.

Authors:  Susanna L Lamers; Ruchi M Newman; Oliver Laeyendecker; Aaron A R Tobian; Robert C Colgrove; Stuart C Ray; David M Koelle; Jeffrey Cohen; David M Knipe; Thomas C Quinn
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

6.  Use of a fragment of glycoprotein G-2 produced in the baculovirus expression system for detecting herpes simplex virus type 2-specific antibodies.

Authors:  Minako Ikoma; Jan-Ake Liljeqvist; Jan Groen; Koen L Glazenburg; T Hauw The; Sytske Welling-Wester
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

7.  Comparative performance of a novel herpes simplex virus type 2-specific enzyme-linked immunosorbent assay using a targeted chain oligopeptide, peptide 55.

Authors:  A M Al-Sulaiman; P J Vallely; P E Klapper
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

8.  Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.

Authors:  Kening Wang; Lesia Dropulic; Joel Bozekowski; Harlan L Pietz; Sinthujan Jegaskanda; Kennichi Dowdell; Joshua S Vogel; Doreen Garabedian; Makinna Oestreich; Hanh Nguyen; Mir A Ali; Keith Lumbard; Sally Hunsberger; Jack Reifert; Winston A Haynes; Jaymie R Sawyer; John C Shon; Patrick S Daugherty; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2021-11-16       Impact factor: 5.226

9.  Type-specific Serologic Testing for Herpes Simplex Virus-2.

Authors:  Peter Leone
Journal:  Curr Infect Dis Rep       Date:  2003-04       Impact factor: 3.663

10.  A general approach for predicting protein epitopes targeted by antibody repertoires using whole proteomes.

Authors:  Michael L Paull; Tim Johnston; Kelly N Ibsen; Joel D Bozekowski; Patrick S Daugherty
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.